Pretreatment Serum Level of 15-kDa Granulysin Might Have a Prognostic Value in Patients with Diffuse Large B Cell Lymphoma

2011 ◽  
Vol 126 (2) ◽  
pp. 79-86 ◽  
Author(s):  
Yong Park ◽  
Yoon Ji Choi ◽  
Se Jong Park ◽  
Se Ryeon Lee ◽  
Hwa Jung Sung ◽  
...  
Keyword(s):  
Serum Level ◽  
B Cell ◽  
Prognostic Value ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Pretreatment Serum ◽  
Large B Cell

Pretreatment Serum Level of Osteopontin and Vascular Endothelial Growth Factor Might Have a Prognostic Value in Patients with Diffuse Large B-Cell Lymphoma

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 1609-1609
Author(s):  
Antica Duletic Nacinovic ◽  
Tajana Juranovic ◽  
Toni Valkovic ◽  
Duska Petranovic ◽  
Ivan Host ◽  
...  
Keyword(s):  
Serum Level ◽  
B Cell ◽  
Cell Lymphoma ◽  
International Prognostic Index ◽  
Prognostic Index ◽  
B Cell Lymphoma ◽  
Serum Levels ◽  
Large B Cell Lymphoma ◽  
Pretreatment Serum ◽  
Large B Cell

Abstract Abstract 1609 Background: Angiogenesis is gaining importance in hematological malignancies; it is regulated by a balance of various enhancing and inhibiting angiogenic factors. However, studies related to the prognostic value of angiogenic factors and aggressive Non-Hodgkin lymphomas are limited compared to solid tumors. The aim of this study was to determine pretreatment serum level of vascular endothelial growth factor (VEGF) and osteopontin (OPN) in patients with diffuse large B cell lymphoma (DLBCL) and to investigate whether these factors provide prognostic information. METHODS: We measured pretreatment serum levels of VEGF and OPN by Enzyme-Linked Immunosorbent Assay (ELISA) in 67 patients newly diagnosed as diffuse large B-cell lymphoma and in 30 healthy controls. All patients were treated with rituximab-CHOP chemotherapy. RESULTS: The serum OPN levels were found elevated in untreated DLBCL patients compared to controls: in newly diagnosed patients it ranged from 25 to 238 pg/ml; median 94.2 pg/ml while in the healthy controls it ranged from 13 to 46.5 pg/ml; median 30.0 pg/ml (P=0.00008). There were significant differences in the serum VEGF levels between DLBCL patients and controls (median 480.96 pg/ml vs. 163.8 pg/ml, P=0.001). Serum OPN levels higher than the median level were related to advanced Ann Arbor stage (P=0.026), International Prognostic Index of 2 or higher (P=0.005), ECOG III-V (P=0.004). The complete remission rate after treatment was higher in patients with low OPN serum levels than in those with high OPN serum levels (67.5% versus 32.4%, P=0.002). Elevated serum levels of OPN were strongly associated with shorter overall survival (P=0.007) and event-free survival (P=0.04). In multivariate analysis with International Prognostic Index criteria, OPN remained a significant predictor for overall survival (P=0.033). VEGF level was significantly correlated with age (P=0.01) and serum lactate dehydrogenase level (P=0.02), but not strongly correlated with other potential prognostic factors, and it failed to show prognostic significance. CONCLUSION: Our results showed that pretreatment serum level of OPN is significantly related to outcome in DLBCL patients. Ongoing extension study and additional follow-up will provide more information moving forward. Disclosures: No relevant conflicts of interest to declare.

scholarly journals PROGNOSTIC VALUE OF RED CELL DISTRIBUTION WIDTH AT DIAGNOSIS (RDW) IN DIFFUSE LARGE B‐CELL LYMPHOMA

2021 ◽  
Vol 39 (S2) ◽  
Author(s):  
J.M. Raya ◽  
P. López‐García ◽  
C. D. Reyes ◽  
M.J. Rodríguez‐Salazar ◽  
C. De Bonis ◽  
...  
Keyword(s):  
B Cell ◽  
Prognostic Value ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Red Cell Distribution Width ◽  
Red Cell ◽  
Cell Distribution ◽  
Distribution Width ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Outcome of R-CHOP or CHOP Regimen for Germinal Center and Nongerminal Center Subtypes of Diffuse Large B-Cell Lymphoma of Chinese Patients

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Ying Huang ◽  
Sheng Ye ◽  
Yabing Cao ◽  
Zhiming Li ◽  
Jiajia Huang ◽  
...  
Keyword(s):  
B Cell ◽  
Germinal Center ◽  
Survival Data ◽  
Prognostic Value ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Chinese Patients ◽  
First Line ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Diffuse large B-cell lymphoma (DLBCL) can be molecularly subtyped as either germinal center B-cell (GCB) or non-GCB. The role of rituximab(R) in these two groups remains unclear. We studied 204 patients with de novo DLBCL (107 treated with first-line CHOP; 97 treated with first-line R-CHOP), patients being stratified into GCB and non-GCB on the basis of BCL-6, CD10, and MUM1 protein expression. The relationships between clinical characteristics, survival data, and immunophenotype (IHC) were studied. The 5-year overall survival (OS) in the CHOP and R-CHOP groups was 50.4% and 66.6% (P=0.031), respectively. GCB patients had a better 5-year OS than non-GCB patients whether treated with CHOP or not (65.0% versus 40.9%;P=0.011). In contrast, there is no difference in the 5-year OS for the GCB and non-GCB with R-CHOP (76.5% versus 61.3%;P=0.141). In non-GCB subtype, additional rituximab improved survival better than CHOP (61.3% versus 40.9%;P=0.0303). These results indicated that addition of rituximab to standard chemotherapy eliminates the prognostic value of IHC-defined GCB and non-GCB phenotypes in DLBCL by improving the prognostic value of non-GCB subtype of DLBCL.

Prognostic value of negative interim 2-[18F]-fluoro-2-deoxy-d-glucose PET/CT in diffuse large B-cell lymphoma

2016 ◽  
Vol 71 (3) ◽  
pp. 280-286 ◽  
Author(s):  
S.H. Kwon ◽  
D.R. Kang ◽  
J. Kim ◽  
J.-K. Yoon ◽  
S.J. Lee ◽  
...  
Keyword(s):  
B Cell ◽  
Prognostic Value ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Pet Ct ◽  
Large B Cell

Prognostic value of pre-therapy C-reactive protein level in diffuse large B-cell lymphoma: a meta-analysis

2018 ◽  
Vol 60 (2) ◽  
pp. 358-366 ◽  
Author(s):  
Wenqiong Qin ◽  
Qiang Yuan ◽  
Jingkui Wu ◽  
Haonan Yu ◽  
Ying Wang ◽  
...  
Keyword(s):  
B Cell ◽  
Protein Level ◽  
Prognostic Value ◽  
Cell Lymphoma ◽  
Meta Analysis ◽  
B Cell Lymphoma ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Prognostic nutritional index and the prognosis of diffuse large b-cell lymphoma: a meta-analysis

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Chunyan Luan ◽  
Fei Wang ◽  
Ning Wei ◽  
Baoan Chen
Keyword(s):  
B Cell ◽  
Prognostic Value ◽  
Cell Lymphoma ◽  
Meta Analysis ◽  
Prognostic Nutritional Index ◽  
B Cell Lymphoma ◽  
Cochrane Library ◽  
Large B Cell Lymphoma ◽  
Nutritional Index ◽  
Large B Cell

Abstract Background Some studies have investigated the prognostic value exhibited by the Prognostic Nutritional Index (PNI) in patients suffering diffuse large B-cell lymphoma (DLBCL), but varying results were obtained. In order to determine the specific prognostic value more accurately, a meta-analysis was conducted in this study. Methods Literatures were searched from the China National Knowledge Infrastructure (CNKI), Wanfang, PubMed, Embase, the Cochrane Library, and Web of Science. Pooled hazard ratio (HR) and the 95% confidence interval (CI) were calculated to assess the association between PNI and the overall survival (OS) and the progression-free survival (PFS) of patients with DLBCL. Results Based on seven studies with a total number of 1311 patients, our meta-analysis revealed that low PNI may meant poor OS (HR = 2.14, 95% CI 1.66–2.75, p < 0.001) and poor PFS (HR = 1.75, 95% CI 1.36–2.25, p = 0.438). Subgroup analysis showed that, in Asians, low PNI was correlated to poor OS (pooled HR = 2.06 95% CI 1.59–2.66) and poor PFS (pooled HR = 1.66, 95% CI 1.28–2.15). Similar results were obtained from one European study, which is the only study performed outside of Asia from our literature search. Conclusion For patients with DLBCL, low PNI may be interpreted as adverse prognosis. More data from European patients are required in this study to avoid analysis bias.

Sign in / Sign up

Export Citation Format

Share Document